Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2008 1
2010 1
2012 1
2013 2
2014 3
2015 1
2016 1
2017 1
2018 2
2019 1
2020 2
2021 5
2022 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic evaluation of besifovir for the treatment of HBV infection.
Mak LY, Seto WK, Lai CL, Yuen MF. Mak LY, et al. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106. doi: 10.1080/17425255.2018.1417983. Epub 2017 Dec 18. Expert Opin Drug Metab Toxicol. 2018. PMID: 29237296 Review.
Besifovir (LB80380) is a relatively new oral acyclic nucleotide phosphonate. ...The most common adverse event is carnitine depletion which affects almost all patients on besifovir requiring carnitine supplementation. Expert opinion: Besifovir demonstrated pre …
Besifovir (LB80380) is a relatively new oral acyclic nucleotide phosphonate. ...The most common adverse event is carnitine depletion …
Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Yim HJ, et al. J Gastroenterol Hepatol. 2022 Feb;37(2):378-386. doi: 10.1111/jgh.15710. Epub 2021 Nov 2. J Gastroenterol Hepatol. 2022. PMID: 34653281
BACKGROUND AND AIM: Besifovir dipivoxil maleate (BSV) was reported to have comparable antiviral efficacy and superior renal and bone safety to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients. ...
BACKGROUND AND AIM: Besifovir dipivoxil maleate (BSV) was reported to have comparable antiviral efficacy and superior renal and bone …
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH. Yim HJ, et al. Am J Gastroenterol. 2020 Aug;115(8):1217-1225. doi: 10.14309/ajg.0000000000000605. Am J Gastroenterol. 2020. PMID: 32355123 Free PMC article. Clinical Trial.
INTRODUCTION: Chronic hepatitis B (CHB) remains a major worldwide public health concern. Besifovir dipivoxil maleate (BSV) is a new promising treatment for CHB. ...
INTRODUCTION: Chronic hepatitis B (CHB) remains a major worldwide public health concern. Besifovir dipivoxil maleate (BSV) is a new p …
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B.
Song JE, Park JY. Song JE, et al. Expert Opin Pharmacother. 2021 Dec;22(18):2427-2433. doi: 10.1080/14656566.2021.1967321. Epub 2021 Aug 19. Expert Opin Pharmacother. 2021. PMID: 34392744
AREAS COVERED: Although the currently available NAs are effective in suppressing viral replication, anti-HBV treatment in principle requires lifelong drug administration, and some patients have limitations such as the incidence of liver cancer and the likelihood of toxicities fol …
AREAS COVERED: Although the currently available NAs are effective in suppressing viral replication, anti-HBV treatment in principle requires …
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Song DS, et al. Clin Mol Hepatol. 2021 Apr;27(2):346-359. doi: 10.3350/cmh.2020.0307. Epub 2021 Jan 25. Clin Mol Hepatol. 2021. PMID: 33493393 Free PMC article. Clinical Trial.
BACKGROUND/AIMS: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. ...
BACKGROUND/AIMS: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepati …
Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir.
Won J, Lee AR, Dezhbord M, Lee DR, Kim SH, Kim JC, Park S, Kim N, Jae B, Kim KH. Won J, et al. Biomedicines. 2022 Jul 7;10(7):1637. doi: 10.3390/biomedicines10071637. Biomedicines. 2022. PMID: 35884942 Free PMC article.
Several mutations in the RT domain which lead to drug resistance against NAs have been reported, even for TDF and TAF which are highly potent with very low resistance rate. Besifovir (BFV) is a new antiviral dGMP analogue able to be used as a new NA drug for the control of …
Several mutations in the RT domain which lead to drug resistance against NAs have been reported, even for TDF and TAF which are highly poten …
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient.
Kim JC, Lee HY, Lee AR, Dezhbord M, Lee DR, Kim SH, Won J, Park S, Kim NY, Shin JJ, Kim SG, Kim YS, Yoo JJ, Kim KH. Kim JC, et al. Biomedicines. 2022 Jan 26;10(2):282. doi: 10.3390/biomedicines10020282. Biomedicines. 2022. PMID: 35203489 Free PMC article.
NAs are potent antiviral agents that bind to HBV polymerase and block viral reverse transcription and replication. Besifovir dipivoxil maleate (BSV) is a newly developed NA against HBV in the form of acyclic nucleotide phosphonate that is available for oral administration …
NAs are potent antiviral agents that bind to HBV polymerase and block viral reverse transcription and replication. Besifovir dipivoxi …
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Ahn SH, et al. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1850-1859.e4. doi: 10.1016/j.cgh.2018.11.001. Epub 2018 Nov 15. Clin Gastroenterol Hepatol. 2019. PMID: 30448598 Free article. Clinical Trial.
BACKGROUND & AIMS: Besifovir dipivoxil maleate (BSV) has activity against hepatitis B virus (HBV). ...
BACKGROUND & AIMS: Besifovir dipivoxil maleate (BSV) has activity against hepatitis B virus (HBV). ...
Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.
Jung YW, Kim M, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Jung YW, et al. J Korean Med Sci. 2020 May 4;35(17):e104. doi: 10.3346/jkms.2020.35.e104. J Korean Med Sci. 2020. PMID: 32356416 Free PMC article.
BACKGROUND: Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral agent for chronic hepatitis B (CHB) infection. ...
BACKGROUND: Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral agent for chronic hepatitis B (CHB) infect …
Influence of Renal Function on the Single-Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection.
Hwang JG, Kim YK, Choi YS, Kwon SK, Han JH, Park MK. Hwang JG, et al. J Clin Pharmacol. 2022 Jan;62(1):46-54. doi: 10.1002/jcph.1945. Epub 2021 Sep 17. J Clin Pharmacol. 2022. PMID: 34327707 Clinical Trial.
An open-label, single-dose parallel-group clinical study was conducted in subjects with normal renal function and mild, moderate, and severe renal impairment. Subjects received a single oral dose of besifovir dipivoxil 150 mg, and serial blood and urine samples were collec …
An open-label, single-dose parallel-group clinical study was conducted in subjects with normal renal function and mild, moderate, and severe …
25 results